Diphenoxylate-Atropine en es it fr

Categoria

Diphenoxylate-Atropine Nombres de marca, Diphenoxylate-Atropine Analogos

Diphenoxylate-Atropine Marca los nombres de mezcla

  • Lomotil (Atropine Sulfate + Diphenoxylate Hcl)
  • Diphenoxylate-Atropine Formula quimica

    C30H32N2O2

    Diphenoxylate-Atropine RX enlace

    http://www.rxlist.com/cgi/generic3/diphenoxylate.htm

    Diphenoxylate-Atropine FDA hoja

    Diphenoxylate-Atropine MSDS (hoja de seguridad de materiales)

    Diphenoxylate-Atropine MSDS

    Diphenoxylate-Atropine Sintesis de referencia

    Janssen, EE.UU. Pat. 2,898,340 (1959)

    Diphenoxylate-Atropine Peso molecular

    452.587 g/mol

    Diphenoxylate-Atropine Punto de fusion

    221 oC

    Diphenoxylate-Atropine H2O Solubilidad

    0,8 mg / ml

    Diphenoxylate-Atropine Estado

    Solid

    Diphenoxylate-Atropine LogP

    7.385

    Diphenoxylate-Atropine Formas de dosificacion

    Solución oral; Tablet

    Diphenoxylate-Atropine Indicacion

    Para la terapia como adyuvante en el tratamiento de la diarrea

    Diphenoxylate-Atropine Farmacologia

    Difenoxilato, un antidiarreico, es eficaz como tratamiento adyuvante en el tratamiento de la diarrea. Difenoxilato es rápida y extensamente metabolizado en el hombre por hidrólisis del éster del ácido diphenoxylic (difenoxine), que es biológicamente activo y el principal metabolito en la sangre.

    Diphenoxylate-Atropine Absorcion

    90%

    Diphenoxylate-Atropine Toxicidad

    Coma, piel seca y las membranas mucosas, dilatación de las pupilas de los ojos, la temperatura corporal extremadamente alta, enrojecimiento facial, movimiento involuntario del globo ocular, menor que el tono muscular normal, pupilas, taquicardia, agitación, lentitud, suprime la respiración

    Diphenoxylate-Atropine Informacion de Pacientes

    INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE RECOMMENDED DOSAGE AND TO KEEP DIPHEN-OXYLATE HCL AND ATROPINE SULFATE OUT OF THE REACH OF CHILDREN AND IN A CHILD-RESISTANT CONTAINER, INFORM THE PATIENT OF THE CONSEQUENCES OF OVERDOSAGE, INCLUDING SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH.

    Diphenoxylate HCl and atropine sulfate may produce drowsiness or dizziness. The patient should be cautioned regarding activities requiring mental alertness, such as driving or operati ng dangerous machinery. Potentiation of the action of alcohol, barbiturates and tranquilizers with concomitant use of diphenoxylate HCl and atropine sulfate should be explained to the patient. The physician should also provide the patient with other information in this labeling, as appropriate.

    Diphenoxylate-Atropine Organismos afectados

    Humanos y otros mamíferos